Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cash & Equivalents: 2009-2024

Historic Cash & Equivalents for Vanda Pharmaceuticals (VNDA) over the last 16 years, with Dec 2024 value amounting to $102.3 million.

  • Vanda Pharmaceuticals' Cash & Equivalents fell 30.32% to $70.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $70.0 million, marking a year-over-year decrease of 30.32%. This contributed to the annual value of $102.3 million for FY2024, which is 24.67% down from last year.
  • Per Vanda Pharmaceuticals' latest filing, its Cash & Equivalents stood at $102.3 million for FY2024, which was down 24.67% from $135.8 million recorded in FY2023.
  • Vanda Pharmaceuticals' Cash & Equivalents' 5-year high stood at $135.8 million during FY2023, with a 5-year trough of $52.1 million in FY2021.
  • Its 3-year average for Cash & Equivalents is $124.4 million, with a median of $135.0 million in 2022.
  • Per our database at Business Quant, Vanda Pharmaceuticals' Cash & Equivalents spiked by 159.32% in 2022 and then decreased by 24.67% in 2024.
  • Yearly analysis of 5 years shows Vanda Pharmaceuticals' Cash & Equivalents stood at $61.0 million in 2020, then dropped by 14.68% to $52.1 million in 2021, then surged by 159.32% to $135.0 million in 2022, then climbed by 0.59% to $135.8 million in 2023, then fell by 24.67% to $102.3 million in 2024.